Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 31, 2000

Filing Date
Filed March 30, 2001
Period End
December 31, 2000
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed March 30, 2001. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported net sales of $306.6 milliona for the fiscal year ended December 30, 2000, up $75.2 million, or 32.5%, from $231.4 million in 1999.

Operating income rose to $65.1 millionb from $43.0 million. The company's research models segment, its historical core business, accounted for 61.2% of 2000 net sales, while biomedical products and services accounted for 38.8%. The biomedical segment grew faster, with net sales of $118.9 million, up 50.7%, and the filing cites a 33.7% compound annual growth rate in net sales over the past five fiscal years.

Acquisitions, including Sierra and the consolidation of Charles River Japan, contributed to the growth. The company posted a net loss of $11.2 millionc in 2000, compared with net income of $17.1 million in 1999. The loss reflects a $29.1 million extraordinary loss, net of tax, from early debt repayment after the June 2000 initial public offering of 16,100,000 shares at $16.00 per share.

Interest expense rose to $40.7 milliond from $12.8 million, reflecting debt taken on in the 1999 recapitalization. Total debt fell to $202.9 million from $386.0 million at the end of 1999, and shareholders' equity was $116.9 million, compared with a deficit of $110.1 million a year earlier. Cash from operations was $33.8 million, and capital expenditures were $15.6 million.

After year-end, the company acquired Pathology Associates International for $37 million and Primedica for approximately $52 million. In March 2001 it completed a public offering of 3,500,000 shares at $19.00 per share, with net proceeds of approximately $62.5 million, which it intends to use to repay debt and retire acquisition obligations. Key risks noted in the filing include the possibility that the IRS challenges a $92.3 million net deferred tax asset tied to a Section 338(h)(10) election, contamination in animal populations, industry consolidation among pharmaceutical customers, and the influence of DLJ Merchant Banking Partners, which beneficially owns approximately 30.0% of common stock.

Key Highlights

  1. Net sales rose to $306.6 million in 2000, an increase of 32.5% from $231.4 million in 1999.
  2. Operating income increased to $65.1 million from $43.0 million, and the operating margin was 21.2% of net sales compared with 18.6% in 1999.
  3. The company reported a net loss of $11.2 million, including a $29.1 million extraordinary loss, net of tax, from early debt repayment after the IPO.
  4. Interest expense increased to $40.7 million from $12.8 million, while total debt decreased to $202.9 million from $386.0 million.
  5. Biomedical products and services net sales grew 50.7% to $118.9 million, and the segment represented 38.8% of 2000 net sales.
  6. The company completed acquisitions of Pathology Associates International for $37 million and Primedica for approximately $52 million in early 2001, and a March 2001 offering raised approximately $62.5 million.
  7. A net deferred tax asset of $92.3 million depends on the Section 338(h)(10) election, which the IRS could challenge, and a successful challenge would require a non-recurring write-off.

Frequently Asked Questions

  1. Why did the company report a net loss in 2000 despite higher operating income?

    The net loss of $11.2 million reflected a $29.1 million extraordinary loss, net of a $15.7 million tax benefit, recorded in the third quarter. The loss arose from premiums on early debt repayment and write-offs of deferred financing costs and issuance discounts after the IPO. Income before the extraordinary item was $17.9 million, and interest expense of $40.7 million also weighed on results.

  2. What are the main sources of revenue for the company?

    Research models, which include purpose-bred rats and mice, produced $187.7 million, or 61.2%, of 2000 net sales. Biomedical products and services, including discovery services, development services, in vitro detection systems and vaccine support products, produced $118.9 million, or 38.8%. Among the four biomedical areas, the filing describes transgenic services as the highest-growth area in discovery services.

  3. How is the company's debt position changing?

    Total debt fell to $202.9 million at December 30, 2000, from $386.0 million a year earlier, after the IPO proceeds were used to repay senior discount debentures, a subordinated discount note and part of the bank debt. The March 2001 offering's proceeds of approximately $62.5 million are intended to repay more indebtedness. Interest rate exposure is partly hedged through an interest rate protection agreement covering at least 50% of term loans and senior subordinated notes, and a hypothetical 100 basis point increase would affect variable rate obligations by approximately $1.3 million.

  4. What are the principal risks highlighted in the filing?

    The filing highlights several risks, including a possible IRS challenge to the Section 338(h)(10) election that underlies a $92.3 million net deferred tax asset, contamination in animal populations that can reduce sales, industry consolidation and reduced research spending by pharmaceutical customers, and the influence of DLJMB Funds, which own approximately 30.0% of common stock. It also cites a single-source supply dependency for one large animal operation and regulatory changes under the Animal Welfare Act.

  5. What recent acquisitions and share transactions occurred after year-end 2000?

    On January 8, 2001, the company acquired Pathology Associates International for $37 million, consisting of $25 million in cash and a $12 million convertible note. On February 27, 2001, it acquired Primedica for approximately $52 million, including $26 million in cash, $16.5 million in restricted stock and $9.5 million in assumed debt. On March 21, 2001, it completed a public offering of 3,500,000 shares at $19.00 per share, and existing shareholders sold 4,550,000 shares in the same offering.